Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and clinical strategies without a dedicated systematic review protocol.
PubMed 42396734 · doi:10.1111/dom.71075
What was done
This narrative review synthesized existing evidence regarding the trajectory, biological mechanisms, and therapeutic implications of weight regain following glucagon-like peptide-1 receptor agonist (GLP-1RA) discontinuation, focusing on treatment de-escalation strategies.
What was found
The abstract provides no numerical data. It notes that weight regain after GLP-1RA cessation is substantial and heavily front-loaded in the initial months. Proposed mechanisms include rapid restoration of appetite, compensatory surges in orexigenic signals (such as ghrelin), shifts in incretin balance (including GIP), and possible GLP-1 receptor adaptations. The review highlights that while reduced-intensity pharmacological maintenance mitigates regain compared with abrupt cessation, structured tapering strategies have not yet been prospectively tested.
Why it matters
Identifying the immediate post-cessation window as a period of acute biological mismatch between elevated appetite signals and lost pharmacological suppression clarifies why abrupt cessation fails and defines the need for evaluated de-escalation protocols.
Limits
The abstract describes a narrative review with no primary data, systematic search parameters, or quantitative effect sizes. Evidence for direct receptor-level adaptations contributing to regain remains limited, and optimal tapering strategies currently lack prospective clinical trial validation.
Cited by
- context Tapering down the dose of GLP-1 drugs helps slow weight regain compared to stopping all at once.